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ABSTRACT
The outcome of patients with anaplastic gliomas varies considerably depending 
on single molecular markers, such as mutations of the isocitrate dehydrogenase (IDH) 
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INTRODUCTION
Anaplastic gliomas of World Health Organization 
(WHO) grade III are currently subdivided into anaplastic 
astrocytic and oligodendroglial (and mixed) tumors [1]. 
The considerable interobserver variation for grading and 
typing of gliomas [2], the variability of outcomes within 
the subgroups and a paucity of therapeutically attractive 
targets derived from this framework have triggered studies 
suggesting a molecularly-based classification for grade II 
and III gliomas. This histological classification and the 
underlying mutations in the isocitrate dehydrogenase 
(IDH) genes 1 and 2 resulting in a glioma CpG island 
methylator phenotype (GCIMP) [3], 1p/19q co-deletions, 
as well as mutually exclusive mutations in telomerase 
reverse transcriptase (TERT) and alpha-thalassemia/
mental retardation syndrome X-linked (ATRX) genes [4, 5] 
are providing a clinically useful prognostic framework [6]. 
Indeed, gliomas across histological subtypes with an IDH 
mutation carry a very similar epigenetic profile [7]. This 
and other studies [8] suggest that IDH mutant gliomas 
form a biologically distinct entity. However, there is still 
value to the WHO grading [52] and a need for deeper 
understanding of the molecular biology of gliomas outside 
the known genetic, epigenetic and transcriptional changes. 
Noteworthy, the majority of transcripts within a cell does 
not represent protein-coding but actually non-coding 
RNA (ncRNA) [9-11]. Amongst those, miRNA gained 
major attraction as they act as mainly inhibitory modifiers 
of translation by steric hindrance of the ribosome or by 
prompting the mRNA degradation [12, 13] which are of 
paramount relevance in cancer [14]. In a tumor setting the 
phenotypic effect of miRNAs depends on the function of 
the inhibited mRNAs. 
The aim of the present work was to better understand 
the transcriptional regulation of miRNAs in gliomas, find 
novel survival marker as well as treatment options. 
RESULTS
Differential methylation of miRNAs in anaplastic 
gliomas
The overlay of differentially methylated regions 
(DMRs) detected in tissue samples from the NOA-04 
trial and putative miRNA promoter regions generated 
an initial list of 29 differentially methylated candidate 
miRNA promoter regions. The DMR data set was 
derived from a MCIp-based DNA methylation profiling 
and the promoter set had been previously identified in 
an H3K4me3 ChIP screen [18]. The candidates were 
prioritized and checked for promoter activity taking 
into account additional factors: a favorable distance and 
orientation of the miRNA gene, adjacent CpG islands, 
the degree of DNase hypersensitivity and vertebrate 
conservation of the target region. The 12 most promising 
miRNA-associated candidate regions with differential 
methylation in anaplastic gliomas were selected for in-
depth analysis (Figure 1, Supplementary Figure 1) and 
validated by quantitative DNA methylation analysis using 
the MassARRAY technology. 
genes, as well as molecular classifications based on epigenetic or genetic profiles. 
Remarkably, 98% of the RNA within a cell is not translated into proteins. Of those, 
especially microRNAs (miRNAs) have been shown not only to have a major influence 
on physiologic processes but also to be deregulated and prognostic in malignancies.
To find novel survival markers and treatment options we performed unbiased 
DNA methylation screens that revealed 12 putative miRNA promoter regions with 
differential DNA methylation in anaplastic gliomas. Methylation of these candidate 
regions was validated in different independent patient cohorts revealing a set of 
miRNA promoter regions with prognostic relevance across data sets. Of those, miR-
155 promoter methylation and miR-155 expression were negatively correlated and 
especially the methylation showed superior correlation with patient survival compared 
to established biomarkers. 
Functional examinations in malignant glioma cells further cemented the relevance 
of miR-155 for tumor cell viability with transient and stable modifications indicating 
an onco-miRNA activity. MiR-155 also conferred resistance towards alkylating 
temozolomide and radiotherapy as consequence of nuclear factor (NF)κB activation. 
Preconditioning glioma cells with an NFκB inhibitor reduced therapy resistance of 
miR-155 overexpressing cells. These cells resembled tumors with a low methylation 
of the miR-155 promoter and thus mir-155 or NFκB inhibition may provide treatment 
options with a special focus on patients with IDH wild type tumors.
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Prognostic relevance of miRNA methylation in 
anaplastic gliomas 
The candidate regions were first analyzed in 
106 patients with anaplastic gliomas from the NOA-
04 trial (Table 1, Supplementary Figure 2, Figure 2A; 
see Supplement for patients’ characteristics). The full 
statistics with all analyzed CpGs and amplicons is 
available in Supplementary Table 1. Due to differences 
in the sample, amplicon and procedure quality reduced 
number of patients with methylation data are present for 
different miRNA candidates of the same patient cohort. 
For all DMR, except the one associated with miR-10b, a 
high methylation was associated with a longer progression 
free survival (PFS) and overall survival (OS). The 
prognostic relevance of selected regions was validated in 
an independent anaplastic glioma patient samples (n = 82) 
from the GGN [16] using the same primers and settings 
as for the initial NOA-04 patients. In the confirmatory 
analysis, low methylation levels at the miR-155 and 
miR-210 promoters were significantly associated with 
worse PFS and OS (Table 1, Supplementary Figure 3; 
see Supplement for patients’ characteristics). Methylation 
levels of the miR-335 promoter region were merely 
correlated with OS.
Correlation with clinically relevant markers showed 
that IDH mutation with the CpG island methylator 
phenotype (CIMP), 1p/19q codeletion, MGMT promoter 
methylation and oligodendroglial histology were 
associated with high miRNA-associated 5’-region 
methylation levels (Figure 2B). 
Furthermore, the relevance of miRNA promoter 
methylation for patients with anaplastic glioma was 
assessed in data available from The Cancer Genome 
Atlas (TCGA). The analysis on TCGA data confirmed the 
negative correlation for miR-155-associated methylation 
in WHO grade III glioma and also showed a lower but 
significant correlation for methylation of the miR-
335 promoter region (Figure 2C). Likewise, also the 
correlation with clinical markers resembled the NOA-04 
situation (Figure 2D). 
In order to test a differential impact on radio- or 
chemotherapy, samples from NOA-04 patients were split 
according to the first line treatment, which showed that 
the survival advantage of the candidate methylation sites 
was independent of treatment modality (first line chemo- 
or radiotherapy) (Supplementary Figure 4). To assess 
an age- or WHO grade-related effect, candidate regions 
were tested on 101 patient samples from the NOA-8 trial 
for patients > 65 years of age with mainly glioblastoma 
(89 %) or anaplastic astrocytoma (11 %) [15]. In these 
patients no correlation of the miRNA methylation status 
with survival was seen (Supplementary Table 2). 
Moreover, testing the prognostic relevance of the 
miR-155-, miR-210- and miR-335- associated 5’ region 
DNA methylation in glioblastoma data available from 
TCGA did not produce significant results for WHO grade 
IV patients (Supplementary Table 3).
Figure 1: miRNA candidates were generated by the overlay of two data sets. The initial list of differentially methylated miRNA 
promoter candidates in anaplastic (anapl.) gliomas originated from an overlay of two distinct screens: a methyl-CpG immunoprecipitation 
screen for differentially methylated regions in anaplastic gliomas from the NOA-04 trial (n = 4; healthy n = 1) vs. an H3K4me3 chromatin 
immunoprecipitation data set from cell lines of different origin (n = 6) and chronic lymphocytic leukemia patients (n = 24; healthy n = 10) 
for putative miRNA promoters. From the 29 candidates (Supplementary Figure 1) produced by this overlay the 12 most favorable candidate 
regions were validated by MassARRAY.
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Figure 2: Low promoter methylation of miR-155, miR-210 and miR-335 was associated with a short patient survival. 
Three promising miRNA candidates were selected and their Kaplan-Meier estimate from the NOA-04 patients calculated A. The statistically 
determined cutpoint (cut) depicts the threshold separating the patients in low and high methylation. The number of patients in each group 
is listed below each graph. Full data for all amplicons are in the supplement. Furthermore, miRNA candidate methylation was plotted 
according to the IDH mutation status, molecular classification (Mol) with CpG island methylator phenotype (CIMP) and 1p/19q codeletion 
status [28], MGMT promoter methylation and tumor histology (histo) B. Additionally, the miRNA methylation for miR-155, miR-210 and 
miR-335 was correlated with the overall survival (OS) by Kaplan-Meier analysis (KM) and Cox regression in 90 patients with anaplastic 
gliomas available from The Cancer Genome Atlas (TCGA) C. and plotted like for the NOA-04 patients. PFS: progression free survival; p.: 
individual p-value; adj. p.: p-value adjusted for testing of multiple amplicons, CpG fragments and cutpoints; IDH: Isocitrate dehydrogenase; 
mut: mutated; wt: wild type; C-: CIMP negative; C+/-: CIMP positive, non-codeleted; C+/+: CIMP positive, 1p/19q codeleted; MGMT: O6-
methylguanine-DNA methyltransferase; m: methylated; u: unmethylated; O(A): oligodendroglioma and oligoastrocytoma; A: astrocytoma; 
r: Pearson’s r correlation.
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Correlation of miRNA-associated DNA 
methylation and miRNA expression
Having established and validated the prognostic 
relevance of differential miR-155, miR-210 and miR-335 
promoter region methylation, we aimed at deciphering 
the functional impact of DNA methylation differences. 
MiRNA promoter methylation and miRNA expression 
were assessed in 12 fresh frozen glioma samples (Figure 
3A). For all candidates the major mature form of the 
respective miRNA transcript was analyzed and if not 
otherwise specified, the miRNA name refers to this form 
throughout the paper (miR-155 for miR-155-5p, miR-210 
for miR-210-3p and miR-335 for miR-335-5p).
High methylation at the miR-155 promoter region 
was linked to low miRNA expression. In addition, the 
correlation of methylation and expression was performed 
with anaplastic glioma patient data available from TCGA, 
which verified the negative correlation for miR-155 and 
also showed a weaker but significant correlation for miR-
335 (Figure 3B). Moreover, TCGA data showed that miR-
155 expression is prognostic and that anaplastic glioma 
patients with a high miR-155 expression feature a poor 
survival (Figure 3C).
Relevance of promoter methylation for miRNA 
expression was also shown in cell lines. Decitabine (5-aza-
2’-deoxycytidine) was applied and DNA methylation was 
determined by MassARRAY and miRNA expression 
by qPCR (Supplementary Figure 5, 6). Cells with an 
initially low miR-155 expression but high methylation 
of the miR-155 promoter region (T98G and U251MG) 
showed a strong increase in miR-155 expression after 
demethylation. For miR-335 also an increase from low to 
higher expression was seen after decitabine treatment of 
highly methylated cell lines.
Figure 3: miR-155 promoter methylation and expression were negatively correlated and prognostic in patients. In a set of 
12 fresh frozen anaplastic glioma samples miRNA expression was determined by qPCR and methylation by MassARRAY A. Additionally, 
the promoter methylation and miRNA expression was correlated in the 90 TCGA patients with anaplastic gliomas B. Moreover, the 
prognostic relevance of the miRNA expression for overall survival (OS) was calculated by Kaplan-Meier analysis (KM) and Cox regression 
in the 90 patients from TCGA C. r: Pearson’s r correlation; p.: p-value; adj. p.: p-value adjusted for testing of multiple variables.
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miR-155 promoter methylation and expression is 
superior to established prognostic markers
In the next step, miRNA markers were analyzed in 
a multivariable analysis on PFS imputing all significant 
co-variables form the NOA-04 trial, namely histology, 
first-line therapy, IDH mutation and MGMT promoter 
methylation status. Putative promoter methylation of miR-
155 and miR-210 were the only significant prognostic 
factors in the respective analyses (Figure 4A). PFS was 
preferred over OS for the NOA-04 calculations since 
the number of OS events is still too low. In addition, we 
analyzed the TCGA data taking IDH status into account 
(Figure 4B). Both, miR-155 promoter methylation and 
miR-155 expression were significant prognosticators in 
this calculation, while methylation and expression of miR-
210 and miR-335 were not. 
Figure 4: miR-155 promoter methylation and expression were strong prognostic factors even in the presence of 
established marker. Multivariate Cox regression models were performed to test the prognostic relevance of the miRNA methylation 
together with established marker. Candidate methylation (meth.), IDH mutation status, MGMT promoter methylation status, histopathology 
and first line treatment were taken into account for the NOA-04 patients (A). From the TCGA data set the miRNA methylation and miRNA 
expression (expr.) were compared against the IDH mutation status (B). Significant correlations were denoted in grey (p-value < 0.05). Both 
multivariable analyses were additionally performed using the molecular classification with CpG island methylator phenotype (CIMP) and 
1p/19q codeletion status (Supplementary Table 4) [28]. Apart from the uni- and mulitvariable Cox regression analysis and all patients, 
also the Hazard ratio of the miR-155 promoter methylation (per 10% methylation increase) was calculated for the IDH wildtype and 
mutant patients of the NOA-04 cohort and the TCGA data. HazR: Hazard ratio; CI: confidence interval; mut: mutated; wt: wild type; m: 
methylated; u: unmethylated; O(A): oligodendroglioma and oligoastrocytoma; A: astrocytoma; RT: radiotherapy; CT: chemotherapy; n: 
number of patients with data for all five factors; events: number of patients with progress/death.
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Additionally for both NOA-04 and TCGA patients, 
the miRNA methylation markers were analyzed applying 
the newly established molecular classification [28] 
(Supplementary Table 4). Also in this multivariable 
analysis miR-155 promoter methylation was superior.
The calculations based on the GGN patient cohort 
investigated here were not significant in the multivariable 
Cox analysis (Supplementary Table 5). However, when 
the prognostic relevance of IDH mutation status and 
MGMT promoter methylation were tested by univariable 
Cox analysis in this cohort, both were not significant 
(Supplementary Table 5). This strongly indicates a non-
regular patient distribution in the investigated subset of the 
GGN cohort concerning these established markers. Thus, 
the multivariable analysis on the GGN patients is to be 
handled with care.
To further determine the IDH independent relevance 
of miR-155 the prognostic value of miR-155 was not only 
analyzed by univariable and multivariable Cox regression 
on all patients but also after separation into IDH wild type 
and IDH mutant patients (Figure 4C). In the IDH wild 
type patients of the NOA-04 and TCGA cohorts, miR-155 
Figure 5: miR-155 was active as onco-miRNA and conveyed therapy resistance. miR-155 high expressing glioma cell lines 
(U87MG, LN-428 and A172) were transfected with scrambled (scr) and anti-miR-155 siRNA (si155) and the viability of the cells measured 
with AlamarBlue A. Additionally, a representative staining is shown B. Stable miR-155 overexpressing (155OE) T98G were generated 
and the proliferation measured in comparison to control cells (ctrl) in the Real Time Cell Analyzer (RTCA) after chemo- (TMZ) and 
radiotherapy treatment C. Moreover, colony formation assays were performed with the control and 155 overexpressing T98G E. For both 
assays a representative experiment is given D., F. p-values < 0.05 are marked by an asterisk. TMZ: temozolomide.
Oncotarget82035www.impactjournals.com/oncotarget
promoter methylation still suggests prognostic relevance. 
In this patient group also a highly differential miR-155 
expression had been observed (Figure 2B). 
miR-155 is active as onco-miRNA
After establishing miR-155 as strong prognostic 
marker, even in comparison to established markers, the 
aim was to better understand the biology behind miR-155 
and deduce its role for reduced patient survival. Glioma 
cell (U87MG, A172 and LN-428) viability was markedly 
reduced after miR-155 levels were transiently knocked 
down by siRNA (Figure 5A, Supplementary Figure 7). 
For in-depth functional analyses a stable 
overexpression of miR-155 in the glioma cell line T98G 
was established (Supplementary Figure 8) and the 
proliferation and clonogenicity analyzed in the presence 
of temozolomide and radiotherapy (Figure 5C-5F). 
Proliferation and clonogenicity assays revealed that miR-
155 confers resistance to both treatment modalities. 
Figure 6: Genes were consistently deregulated according to miR-155 expression status in patients and in vitro. Gene 
expression data from patients with anaplastic gliomas of TCGA was used to calculate the degree of positive (0.4 to 1) or negative (-1 to -0.4) 
correlation with miR-155 expression A. The analysis was performed individually for IDH mutant (mut) and IDH wild type (wt) patients. 
Each dot represents a gene and displays its correlation with miR-155 expression in IDH mutant (y-axis) and wild type patients (x-axis). 
Microarray analyses were performed with control (ctrl) T98G and miR-155 overexpressing (OE) T98G after treatment with chemo- (TMZ) 
or radiotherapy including the respective mock treatments B. The transcriptome of the samples from three independent experiments were 
clustered in a heatmap. Next, the in vitro microarray and the correlation in patients were combined to uncover relevant transcriptional 
changes due to miR-155 expression C. Candidates were validated by qPCR. The microarray and qPCR data represent fold change of the 
gene expression from the miR-155 overexpressing cells to the control cells. For the patient data the degree of correlation of the expression 
of each gene with the miR-155 expression is given. Marked are BEX1, ATL1 and TSPAN7 with a significant miR-155 dependent down 
deregulation in all in vitro treatment groups and the IDH wild type patients. An upregulated expression or positive correlation (cor.) with 
miR-155 expression was colored in red and the opposite in green. Genes without data were denoted in gray. TMZ: temozolomide; mut: 
mutation.
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miR-155 as master modulator induces NFκB 
activity
To further elucidate the effect of miR-155 
overexpression in glioma cells the transcriptional changes 
upon miR-155 expression were analyzed in vitro and 
in patient-derived tissue data. To capture the latter, the 
anaplastic glioma TCGA data was used to determine 
which genes were positively or negatively expressed 
together with miR-155. Since recent data of our group [29] 
and others [30-32] indicate that the IDH or GCIMP status 
separates two distinct patient groups, tissues were split 
into IDH wild type and IDH mutant tumors. Especially in 
the IDH wild type patients a high number of genes were 
found whose expression was either positively (0.4 to 1) 
or negatively (-1 to -0.4) correlated to the expression of 
miR-155 (Figure 6A). This patient group had initially also 
featured a differential miR-155 promoter methylation in 
contrast to the IDH mutant tumors, which had a uniformly 
high miR-155 promoter methylation (Figure 2B).
For the in vitro situation microarray expression 
analyses were performed with the control and miR-155 
overexpressing cells after mock treatment and chemo- or 
radiotherapy showing a high number of transcriptional 
changes upon miR-155 expression in the heatmap (Figure 
6B). 
Combining cell line and patient data sets revealed 
several genes with coregulation (Figure 6C). The genes 
present in the table were additionally all validated by 
qPCR in the cell line. Three genes were consistently 
strongly deregulated upon stable in vitro miR-155 
expression and in the miR-155 expressing IDH wild 
type tumors: brain-expressed X-linked protein (BEX)1, 
Figure 7: NFkB activation was found as common theme upon miR-155 expression. The in vitro and patient data were 
analyzed with Ingenuity Pathway Analysis (IPA). From the microarray genes consistently deregulated in all groups were used (before 
multiple testing correction). The analysis revealed in both sets as upstream regulator the activation of NFκB upon miR-155 expression 
A. Immunoblot analysis of the p65 subunit phosphorylation (p-NFκB p65) confirmed the NFκB activation in miR-155 overexpressing 
(155OE) cells in comparison to control (ctrl) cells B. The cells were seeded for colony formation assay and pretreated with the NFκB 
inhibitor JSH-23 or DMSO as control followed by the standard chemo- (TMZ) and radiotherapy C. The ratio of colonies from miR-155 
overexpressing cells (OE) to control cells (ctrl) was calculated for each treatment. p-values < 0.05 are marked by an asterisk. NKIRAS1 
was recently confirmed as miR-155 target [33]. Apart from analysis on RNA level in cells (fold change 155OE to ctrl) and patients 
(correlation with miR-155) D., NKIRAS1 protein levels were also determined in vitro in the control and miR-155 overexpressing cells E. 
cor.: correlation with miR-155 expression.
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atlastin (ATL)1 and tetraspanin (TSPAN)7 (Figure 6C). 
Yet, these genes were not found to be direct canonical 
miR-155 targets in different miRNA target predictions 
(miRTarBase, targetscan, TarBase, miRDB and Pictar). 
To elucidate the underlying miR-155 molecular pathway 
effects, transcriptome data was analyzed by Ingenuity 
Pathway Analysis (IPA) indicating activation of the NFκB 
pathway upon miR-155 expression (Figure 7A). This was 
confirmed by immunoblot analysis for the phosphorylation 
of the NFκB subunit p65, marker for an active canonical 
NFκB pathway, in the control and miR-155 overexpressing 
cells (Figure 7B). Moreover, pretreating glioma cells with 
the NFκB inhibitor JSH-23 specifically reduced therapy 
resistance in miR-155 overexpressing cells (Figure 7C). 
Apart from the NFκB inhibitor BEX1 determined above, 
it was recently published that NFκB inhibitor interacting 
Ras-like 1 (NKIRAS1) is a direct target of miR-155 
[33]. Although the reduction at the RNA level was only 
marginal in the miR-155 expressing cells, immunoblot 
analysis showed a strong reduction of NKIRAS1 at the 
protein level after miR-155 overexpression (Figure 
7D, 7E). Moreover, in IDH wild type anaplastic glioma 
patients NKIRAS1 expression was negatively correlated 
with miR-155 expression at the RNA level (Figure 7D).
DISCUSSION
In this NOA-04 dataset-based epigenome-wide DNA 
methylation screen, methylation of the miR-155 promoter 
was established as strong prognostic marker in patients 
with anaplastic gliomas in three independent patient 
cohorts. Mir-55 promoter methylation showed stronger 
effects than IDH mutation status, MGMT promoter 
methylation and histopathology. In functional analyses the 
onco-miRNA activity of miR-155 was confirmed and the 
promotion of therapy resistance upon miR-155 expression 
was associated with increased NFκB activity.
Several recent studies [30-32] have established a 
classification for anaplastic gliomas consisting of three 
classes, separable by IDH mutation or GCIMP and 1p/19q 
deletion status as well as presence of absence of copy 
number variations typical for glioblastoma. Importantly, 
this molecular classification signifies clinically relevant 
survival differences and is superior to the current 
histopathological subtyping [29]. The present study 
focussed on differentially methylated candidates outside 
IDH and 1p/19q in the non-coding regions of the DNA. 
The advantage of methylation biomarkers lays in 
the easy determination by pyrosequencing / MassARRAY 
and putative stability over time. In chronic lymphocytic 
leukemia DNA methylation of a single CpG in the 
promoter of ZAP-70 predicts the outcome [34, 35]. 
Similarly, an HPV-related methylation signature predicts 
survival in oropharyngeal squamous cell carcinomas [36].
Independent from later miRNA studies already the 
primary transcript of miR-155, B-cell integration cluster 
(BIC), was marked as proto-oncogene in chicken B-cell 
lymphomas induced by the avian leukosis virus [37, 38]. 
With the upcoming miRNA research, the mature miR-155 
was deducted from BIC also in mouse and human [39]. 
The antisense strand of the miR-155 duplex (miR-155-3p), 
which is expressed only at minor levels in comparison to 
miR-155 (miR-155-5p) [40, 41]. miR-155 was found to 
be overexpressed in leukemia and lymphoma, but also in 
solid tumors of the lung and breast as well as in glioma 
[42].
The functional data with transient and stable miR-
155 expression modulations are in line with the so far 
only transient anti-miR-155 siRNA studies. U87MG 
showed reduced proliferation upon miR-155 inhibition 
with unmodified siRNAs, as well as a diminished 
migration and invasion but increased apoptosis [43-45]. 
Also miR-155 knockdown in U251MG cells resulted in 
reduced proliferation and enhanced chemo-sensitivity 
[46]. However, in our hands U251 belonged to the group 
of cell lines with a high methylation and minimal miR-155 
expression levels [43-45].
One initial drawback of the analyses was the 
existence of the GCIMP in IDH mutated gliomas [3, 
47], which rendered differential methylation of most 
attractive candidates in the past just an epiphenomenon 
of co-methylation despite the potential functional or 
clinical relevance. Here, we identified a candidate, miR-
155, which showed prognostically relevant differential 
promoter methylation in anaplastic gliomas superior to 
established marker. This makes miR-155 a particularly 
attractive candidate since apart from MGMT there is no 
other DNA methylation-regulated candidate marker with 
relevance outside the IDH-effect. The mechanisms, by 
which MGMT and miR-155 are regulated, remain to be 
determined [48]. 
Interestingly, the analysis of TCGA glioblastoma 
patients, who are mainly IDH wild type patients, did 
not reveal prognostically relevant differential miR-155 
promoter methylation (Supplementary Table 3), indicating 
a marker with some selectivity for anaplastic glioma. The 
same was seen for malignant gliomas in elderly patients 
(Supplementary Table 2). This patient group with nearly 
no IDH mutations had been shown to be especially 
troublesome, since the generally low DNA methylation 
levels in their tumors prevented proposed gene candidates 
from being prognostic [49].
One of the earliest onco-miRNA representative is 
miR-21, whose aberrant expression was first described in 
a miRNA screen on glioblastoma patient samples yielding 
miR-21 as the candidate showing strongest upregulation in 
glioblastoma and demonstrating a functional dependency 
of glioblastoma cells on its expression [50]. Apart from 
miR-155 also other miRNAs with promising results in 
our methylation screen, like miR-210 and miR-335, have 
been determined as functional onco-miRNA in glioma 
[51, 52]. Moreover, the TCGA studies on large cohorts of 
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Figure 8: Potential association between patient survival and miR-155. Initially, a short patient survival was correlated with a low 
DNA methylation at the miR-155 promoter. In the following, patient and in vitro data showed that an absence of this inhibitory methylation 
allowed the expression of miR-155. The expression of miR-155 negatively regulated target mRNAs and led to major expression changes 
in the cells. In particular, down regulation of NFκB inhibitors enabled the activation of NFκB. This caused an increased resistance against 
standard clinical therapies and enabled a stronger tumor cell survival, which would explain the short patient survival.
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patients with glioblastoma, followed by numerous articles 
making use of the publically available data, and recently 
WHO grade II and III glioma highlight the deregulation 
and involvement of multiple miRNAs species in gliomas 
[31, 53, 54]. 
Limitations to our data are the retrospective nature 
of the analyses as well as the multiple analyses performed 
on the NOA-04 biomarker data set. To overcome these 
limitations, data were corrected for multiple testing and 
stringent criteria were used for the confirmation of the data 
in independent cohorts. Starting from two unsupervised 
analyses, candidates were narrowed down by challenging 
in other datasets and finally cell line experiments. 
Therefore, it cannot be excluded that though aiming to be 
comprehensive, we may have omitted candidates that may 
be of value. Sample size especially with focus on event 
rates and numbers in the individual subgroups, although 
considerable in total, may have been too low to decipher 
predictive effects of miR-155 or any other candidates. 
As opposed to TCGA and NOA-04, the subpopulation 
of the GGN cohort investigated in this study did not 
feature a known distribution of the established biomarker 
IDH mutation and MGMT promoter methylation 
(Supplementary Table 5). The consistent prognostic value 
of miR-155 promoter methylation in this cohort further 
underlines its relevance even beyond the clinical study 
situation (NOA-04) and research oriented patient selection 
(TCGA).
Besides, the cut-off methylation level of 67% 
methylation at the miR-155 promoter, applied to split 
the patients into the “low” and the “high” methylated 
group, was determined statistically to generate the 
Table 1: Prognostic miRNA promoter methylation was determined for patients with anaplastic gliomas of the NOA-04 
trial and validated in a GGN cohort. 
The methylation of the candidate regions was analyzed by MassARRAY in patient samples of the NOA-04 cohort [51] and 
afterwards validated in patients from the GGN [49]. By a Cox regression model the mean methylation of each candidate region 
was correlated with the progression free and overall survival and the p-value corrected for testing of multiple candidates. 
Significant correlations were denoted in grey (adj. p-value < 0.05). The results for all analyzed CpGs and amplicons is given 
in the supplement. Obs: observation, number of patients with full data; HazR: Hazard ratio; CI: confidence interval; p-value 
adj: p-value adjusted for testing of multiple amplicons and CpG fragments
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strongest significance in the NOA-04 cohort (Figure 2). 
Consequently, although this cut-off value was subsequently 
confirmed in the GGN cohort (Supplementary Figure 
3), further validation and presumably adjustment are 
necessary, to best serve the actual patient situation. The 
choice of glioblastoma cell lines instead of cell lines 
from anaplastic gliomas was made based on the limited 
availability of manageable WHO grade III cells in culture 
and the strong effect of miR-155 in IDH wild type 
anaplastic gliomas.
Future challenges will be the integration of 
information of this kind into prospective trials and later 
into the glioma classification and the present set of 
clinically applicable biomarkers. Moreover, a proof-
of-concept clinical trial is needed to address the value 
of NFκB or even more distal inhibition in the treatment 
of patients with miR-155 overexpressing gliomas. Yet, 
miRNA-based treatments are coming of age and are 
entering the clinic. Miravirsen, a miR-122 antisense 
therapy for hepatitis C with hepatitis C virus infection, 
has recently shown promising results in a phase 2a trial 
[55]. Additionally, the first miRNA-based cancer therapy 
MRX34 is in the late stage of a phase I trial on liver 
cancer and liver metastasis [56]. The blood-brain-barrier 
constitutes a major hurdle for the treatment of gliomas 
but already several strategies are pursued with exosome 
/ liposome particles, polymer based vectors and viral 
systems being at a special focus nowadays [57-59].
For testing of miR-155 promoter methylation levels, 
the technically easiest and least tissue consuming analyses 
would be MassARRAY technology or pyrosequencing, 
both being applicable to formalin-fixed paraffin embedded 
tumor tissue [19]. Methylation specific PCR is not 
recommended since it does not generate quantitative 
results but only produces a binary output: unmethylated 
or methylated [60].
In summary (Figure 8), miR-155 promoter 
methylation and anaplastic glioma patient survival were 
correlated and a lower miR-155 promoter methylation 
was associated with worse prognosis. We further 
observed that miR-155 promoter methylation and miR-
155 expression were negatively correlated, and that high 
promoter methylation reduced the expression of miR-
155. Further, high miR-155 expression was associated 
with strong transcriptional changes and NFκB pathway 
activation mediating chemo- and radiotherapy resistance. 
We hypothesize that these observations explain why 
patients with anaplastic gliomas featuring high miR-155 
expression demonstrate reduced survival.
MATERIALS AND METHODS
Patients and tumor samples
Glioma tissue samples were acquired from the two 
clinical trials NOA-04 and NOA-08 and additionally the 
prospective cohort study of the German Glioma Network 
(GGN). The clinically related research in this work is 
covered by the ethics votes for NOA-04 [6], NOA-08 [15] 
and the GGN [16] (for molecular characteristics see the 
supplement).
As opposed to TCGA and NOA-04, the 
subpopulation of the GGN cohort investigated in 
this study did not show a known distribution of the 
established biomarker IDH mutation and MGMT promoter 
methylation (Supplementary Table 5). 
Purification of DNA and RNA
DNA from formalin fixed paraffin embedded patient 
tissue was purified from representative tumor areas with 
the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). 
DNA together with RNA > 200 bp and RNA < 
200 bp was purified from fresh frozen patient tissue and 
cell lines with the AllPrep DNA/RNA Mini Kit (Qiagen) 
together with the RNeasy MinElute Cleanup Kit (Qiagen) 
according protocol to the standard protocol. For samples 
where DNA was not needed, then miRNAs were purified 
with the miRNeasy Mini Kit (Qiagen, Hilden, Germany) 
together with the RNeasy MinElute Cleanup Kit (Qiagen) 
to obtain an RNA fraction < 200 bp and > 200 bp. For 
an extraction of only RNA > 200 bp, the RNeasy Kit 
(Qiagen) was used.
Methyl-CpG immunoprecipitation (MCIp) and 
CpG island array hybridization
Methyl-CpG immunoprecipitation (MCIp) with 2.5 
μg genomic DNA, array hybridization using CpG island 
arrays (Agilent, Waldbronn, Germany) and data evaluation 
were essentially performed as described previously [17]. 
Enrichment of methylated DNA fragments was controlled 
by qPCR analyzing the differentially methylated sequence 
in the gene PCDHGA11 and on the other hand GAPDH 
as a marker for unmethylated fragments. Differentially 
methylated regions (DMRs) were defined and identified 
as described [17]. The array data have been deposited 
in NCBI’s Gene Expression Omnibus under accession 
number GSE79080.
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MiRNA promoter data and generation of 
differentially methylated miRNA promoter 
candidates from data set overlay
For miRNA promoter identification, the H3K4me3 
ChIP data set previously published by Baer et al [18] 
was utilized. These data were generated using an Agilent 
custom-design 244k array covering genomic loci of 
939 annotated miRNAs from miRBase 15 (http://www.
mirbase.org/). The sequences represented on the array 
included 35 kb upstream and 5 kb downstream of the pre-
miRNAs and 2 kb up- and downstream of transcriptional 
start sites of miRNA hosting genes. The array design is 
available at Agilent’s array platform (AMADID029434 for 
hg19). Analysis of H3K4me3 ChIP data was performed 
with the CoCAS ChIP-on-chip analysis suite as described 
previously [18]. In total, 781 putative miRNA promoter 
regions were identified. For detection of overlaps of 
genomic features (differentially methylated regions and 
putative miRNA promoter regions) a custom PERL script 
based on pair wise comparison of the genomic coordinates 
was used (script is available on demand).
MassARRAY DNA methylation analysis
DNA of formalin fixed paraffin embedded patient 
tissue was bisulfite converted using the Epitect Bisulfite 
Kit (Qiagen). DNA methylation was quantitatively 
measured with the MassARRAY system (Sequenom) as 
previously described [19]. Primer sequences are listed in 
the supplementary material.
In vitro work
LN-308, LN-319, LN-428, D247 and U373 glioma 
cells were kindly provided by Prof. Nicolas de Tribolet 
(Lausanne, Switzerland). LN-229, LN-18, U138 MG, 
T98G, A172 and U87MG cells were purchased from the 
American Type Culture Collection (ATCC; Manassas, 
VA, USA). Regular checks for cell line authenticity and 
freedom from infection, e.g. mycoplasms, were done 
according to the institutional guidelines at the German 
Cancer Research Center.
For inhibition of DNA methylation by 5-aza-2′-
deoxycytidine (decitabine) cells were seeded in 6-well 
plates with two wells for each condition. The cells were 
incubated with 0,5µM decitabine or DMSO as control 
treatment and the medium was exchanged every day. 
T98G, U251 and U138 were treated three days and A172 
and U87MG for five days. 
MiR-155 (miR-155-5p) specific siRNA and control 
siRNA were purchased from Exiqon (Vedbaek, Denmark; 
miRCURY LNA Power inhibitors). These siRNAs are 
based on the Locked Nucleic Acid (LNA) technology 
from Exiqon and feature a fully phosphorothioate (PS) 
modified backbone. For stable miR-155 overexpression 
the glioma cell line T98G was transfected with the pre-
miR-155 containing episomal vector pREP4 (Invitrogen, 
Carlsbad, CA, USA) for miR-155 overexpression and 
the prep4 backbone as control. The ready-to-use vector 
was kindly provided by Jan Meier [20]. Further details on 
transfection procedures and assay procedures are found in 
the supplement.
Quantitative reverse transcription polymerase 
chain reaction
The miRNA fraction was reversely transcribed 
with the Universal cDNA Synthesis Kit II (Exiqon A/S, 
Vedbaek, Denmark) and the expression then analyzed with 
the miRCURY LNA™ Universal RT microRNA PCR Kit 
and respective primer (Exiqon) on a StepOnePlus Real-
Time PCR System (Applied Biosystems, Carlsbad, CA, 
USA). 
miR-16 was established as reference with 
BestKeeper [21] analysis due to is high reproducibility and 
low variance after the evaluation of miR-16, U6 snRNA, 
SNORD48, 5S RNA and let7a. Moreover, using RNA 
species longer than miRNAs, e.g. U6 snRNA, was not 
recommended due to potential differences in extraction 
and reverse transcription (e.g. see Exiqon miRNA qPCR 
guidelines). Besides, retesting the effect of decitabine 
demethylation using U6 as reference gene resulted in 
comparable effects for miR-155 expression. 
RNA was transcribed with the High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, 
Warrington; UK) and the ABsolute qPCR SYBR Green 
Mix (Thermo Scientific, Waltham, USA) used for 
expression analysis relative to GAPDH. Primer sequences 
are listed in the supplement.
The miRNA name refers to this form throughout the 
paper (miR-155 for miR-155-5p, miR-210 for miR-210-3p 
and miR-335 for miR-335-5p).
Immunoblot
Cell lysates and immunoblots were performed as 
described previously [22]. Antibodies: α-Tubulin 1:1000 
(#3873; Cell Signaling, Cambridge, UK), β-actin 1:1000 
(sc-1616; Santa Cruz, Dallas, Texas, USA), p-NF-κB p65 
(L8F6) 1:1000 (#3033; Cell Signaling, Cambridge, UK); 
NKIRAS1 1:1000 (GTX113962; Genetex, Irvine, CA, 
USA).
TCGA collective
Methylation (Illumina HumanMethylation450 
BeadChip), miRNA expression (miRNASeq), mutational 
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(IDH) and survival data have been obtained from The 
Cancer Genome Atlas dataset at April 15th, 2013 (http://
cancergenome.nih.gov).
Microarray analysis
Cells were treated as described for the proliferation 
assay and prepared as described before [22]. The 
microarray data have been deposited in NCBI’s Gene 
Expression Omnibus under accession number GSE79081. 
A detailed description is found in the supplement.
Statistical analysis
MassARRAY CpG units were evaluated separately 
as well as averaged per amplicon. Association of 
quantitative DNA methylation measurements with overall 
survival (OS) and progression-free survival (PFS) was 
assessed with univariable Cox PH regression models. 
Proportional hazards assumption was tested for violation 
according to Grambsch and Therneau [23]. Risk groups 
were determined based on optimal cut-point analysis 
using the maximally selected log-rank statistic approach, 
which corrects for type I error inflation due to multiple 
testing [24]. Survival of risk groups was estimated with 
the method of Kaplan and Meier. Univariable p-values 
were adjusted for multiple testing across all amplicons 
using Benjamini-Hochberg correction in order to control 
the false discovery rate [25]. Multivariable Cox regression 
was used to adjust for clinico-pathological factors. All 
tests were two-sided. P-values below 0.05 were considered 
statistically significant. Analyses were carried out using 
software R Version 2.14 using add-on package rms [26].
For the TCGA data, correlation of methylation and 
expression was analyzed per cg probe with Pearson’s 
correlation coefficient. Illumina cg probes were selected 
to cover the MassARRAY amplicon. For methylation 
data, the M value = log2 (Methylated Intensity+1) 
/ (Unmethylated Intensity+1) was used, for miRNA 
expression normalized counts (reads per million miRNA 
mapped). Survival analysis employed Cox proportional 
hazards regression and the log-rank test with maximally 
selected rank statistics (R package “maxstat”), which 
corrects for Type-I-error inflation [24]. Violation of the 
proportional hazards assumption was tested according to 
Grambsch and Therneau [23]. To adjust for type-I-error 
inflation, the Bonferroni procedure was used. All tests 
were two-sided, and a p value < 0.05 was considered 
significant. Analyses were carried out using R version 
3.0.2 [27].
The in vitro experiments were conducted in at least 
three independent experiments if not otherwise indicated. 
Two-sided Student’s t test was applied for statistical 
evaluation. Values p < 0.05 were considered significant 
and marked with asterisks. All error bars shown in figures 
represent standard deviation.
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